Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2014

View Archived Issues

World Parkinson's Day News: recent pathological insights and repurposing efforts

ASP-8273 efficiently induces and maintains tumor growth regression in mutant EGFR NSCLC models

Bristol-Myers Squibb presents first-in-human results for the anti-atherosclerosis agent BMS-962476

Dana-Farber awarded research grant to study cancer vaccine

Mutation in HIBCH gene identified in patient with Leigh syndrome

Novartis presents a novel covalent inhibitor of mutant-selective EGFR for the treatment of NSCLC

PRX-002 enters phase I for Parkinson's disease

Alpha-1-acid glycoprotein investigated as a breast cancer biomarker

Data and safety monitoring board recommends continuation of ixCELL-DCM trial

Biogen Idec and Sobi report topline results from phase III Eloctate trial

Investigator-initiated study begins for BL-8040 in chronic myeloid leukemia

Researchers at Genzyme disclose new GCS inhibitors

Novel BTK inhibitors presented by Roche

Scientists at Roche design novel agents for CNS disorders

Assembly Pharmaceuticals raises funds to advance drugs for HBV

Bristol-Myers Squibb divulges new Notch signaling inhibitors for cancer

Tetra Discovery collaborates with Broad Institute's Stanley Center on schizophrenia

AVEO Oncology and Biodesix partner on development of ficlatuzumab and companion diagnostic test

APEPTICO reports topline results from phase IIa study of AP-301

Xencor receives milestone payment under XmAb antibody product agreement

Ironwood Pharmaceuticals synthesizes novel sGC activators for PAH and other disorders

Neurolixis receives grant to test NLX-101 in animal models of Rett syndrome

DNA gyrase inhibitors show activity against M. kansasii

Pfizer returns Aversion product rights to Acura Pharmaceuticals

FDA accepts Stemline Therapeutics' IND for phase II trial of SL-701 for GBM

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...